Inventor · disambiguated record
Erwin R. Boghaert
Also filed as: BOGHAERT ERWIN · BOGHAERT ERWIN R · BOGHAERT ERWIN R A · BOGHAERT ERWIN RAYMOND A
9 granted patents·32 pending applications·99 citations·filing 2005–2024
88Inventor score
Top patents by PatentIndex Score
41 records- 0195US8044178B2Anti-5T4 antibodies and uses thereofWYETH LLC·Filed 2007·Granted Oct 25, 2011·41 cites·31 claims
- 0291US8759495B2Anti-5T4 antibodies and uses thereofBOGHAERT ERWIN R·Filed 2011·Granted Jun 24, 2014·22 cites·33 claims
- 0390US9132190B2Therapeutic DLL4 binding proteinsABBVIE INC·Filed 2013·Granted Sep 15, 2015·13 cites·46 claims
- 0489US11633497B2Anti-c-Met antibody drug conjugatesABBVIE INC·Filed 2022·Granted Apr 25, 2023·1 cites·8 claims
- 0588US8623358B2Therapeutic DLL4 binding proteinsBENATUIL LORENZO·Filed 2010·Granted Jan 7, 2014·13 cites·44 claims
- 0684US2025177374A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2024·Application pending·0 cites
- 0783US9902771B2Anti-5T4 antibodies and uses thereofWYETH LLC·Filed 2015·Granted Feb 27, 2018·3 cites·20 claims
- 0881US2025213685A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2024·Application pending·0 cites
- 0981US2025263491A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2024·Application pending·0 cites
- 1080US9469688B2Therapeutic DLL4 binding proteinsABBVIE INC·Filed 2015·Granted Oct 18, 2016·2 cites·37 claims
- 1178US2025170263A1Anti-egfr antibody-drug conjugatesABBVIE INC·Filed 2024·Application pending·0 cites
- 1277US2024058450A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2022·Application pending·0 cites
- 1375US2024115725A1Anti-EGFR Antibody-Drug ConjugatesABBVIE INC·Filed 2023·Application pending·0 cites
- 1474US11759527B2Anti-EGFR antibody-drug conjugatesABBVIE INC·Filed 2022·Granted Sep 19, 2023·0 cites·3 claims
- 1574US2024199745A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2023·Application pending·0 cites
- 1673US9340774B2Tumor-initiating cells and methods for using sameDAMELIN MARC ISAAC·Filed 2010·Granted May 17, 2016·4 cites·11 claims
- 1773US2020246460A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2019·Application pending·0 cites
- 1873US2023372519A1Anti-c-met antibody drug conjugatesABBVIE INC·Filed 2023·Application pending·0 cites
- 1972US2023114718A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2022·Application pending·0 cites
- 2070US2023077680A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2021·Application pending·0 cites
- 2165US2010173382A1Humanized anti-5t4 antibodies and anti-5t4/calicheamicin conjugatesWYETH CORP·Filed 2009·Application pending·0 cites
- 2265US2020255508A1Therapeutic DLL4 Binding ProteinsABBVIE INC·Filed 2019·Application pending·0 cites
- 2364US2020239553A1BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2019·Application pending·0 cites
- 2464US2009105461A1Calicheamicin conjugatesWYETH CORP·Filed 2008·Application pending·0 cites
- 2564US2010021483A1Humanized anti-5t4 antibodies and anti-5t4/calicheamicin conjugatesWYETH CORP·Filed 2009·Application pending·0 cites
- 2662US2014308302A1Anti-5t4 antibodies and uses thereofWYETH LLC·Filed 2014·Application pending·0 cites
- 2762US2019142941A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2019·Application pending·0 cites
- 2862US2020246323A1Antibody Drug Conjugates with Cell Permeable BCL-XL InhibitorsABBVIE INC·Filed 2019·Application pending·0 cites
- 2961US2018162937A1Anti-5t4 antibodies and uses thereofWYETH LLC·Filed 2018·Application pending·0 cites
- 3059US2018371071A1Therapeutic DLL4 Binding ProteinsABBVIE INC·Filed 2017·Application pending·0 cites
- 3157US2019153108A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2017·Application pending·0 cites
- 3256US2007190060A1Passive targeting of cytotoxic agentsWYETH CORP·Filed 2005·Application pending·0 cites
- 3355US2006002942A1Calicheamicin conjugatesWYETH CORP·Filed 2005·Application pending·0 cites
- 3455US2006088522A1Humanized anti-5T4 antibodies and anti-5T4/calicheamicin conjugatesWYETH CORP·Filed 2005·Application pending·0 cites
- 3553US2019343961A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2017·Application pending·0 cites
- 3653US2016339117A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2015·Application pending·0 cites
- 3750US2016326496A1Tumor-initiating cells and methods for using sameWYETH LLC·Filed 2016·Application pending·0 cites
- 3848US2019153107A1Anti-egfr antibody drug conjugatesABBVIE INC·Filed 2017·Application pending·0 cites
- 3944US2007003559A1Methods of determining pharmacokinetics of targeted therapiesWYETH CORP·Filed 2006·Application pending·0 cites
- 4042US2017182179A1Antibody Drug Conjugates with Cell Permeable BCL-XL InhibitorsABBVIE INC·Filed 2015·Application pending·0 cites
- 4142US2016158377A1BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the SameACKLER SCOTT L·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →